The sensitivity was improved (-10 nmol/L), but the complexity of the method and the need for a gradient elution led to a total run time >70 mm (17). Other HPLC procedures include a conventional separation, with the collection of the dl-FA peak followed by the concentration of the dl-FA and its reirLjection onto a BSA stationary phase; the concentration of dl-FA is achieved either by a single evaporation on Bond Elut RP-18 cartridges (no. Al 1210-2028) that had first been conditioned with methanol (4 x 2 mL) and 100 mmoIIL TriSP, pH 4.7(3 x 2 mL). The cartridge was rinsed with 0.5 mL of 10 mmol/L TrisP, pH 4.7, and eluted with 1.5 mL of methanol:10 mmo]/L TrisP (75:25, vol:vol), pH 7, contaming 0.15 g/L ascorbic acid. The eluates were evaporated at 37 #{176}C under a nitrogen stream for 30 mm. Dry residues were dissolved in 250 L of 9 gIL NaC1 containing 1 g/L ascorbic acid (twofold-concentrated samples). Forty microliters was injected onto the chromatographic system. Quantification of plasma samples was done by regression analysis based on a calibration curve in plasma. The calibration curve was prepared for each run by adding pure dl-FA (racemic mixture, 50/50) and 5MTHF from Sigma to blank plasma.
. In addition to stereospecific differences in biological activity, FA has stereospecific pharmacokinetics (6) (7) (8) , with plasma half-life of l-FA being significantly shorter than (17) , who performed the chiral H.PLC on the BSA column and then used postcolumn peak compression and elution on two RP-18 HPLC columns so that the stereoisomers were trapped and compressed.
The sensitivity was improved (-10 nmol/L), but the complexity of the method and the need for a gradient elution led to a total run time >70 mm (17). Other HPLC procedures include a conventional separation, with the collection of the dl-FA peak followed by the concentration of the dl-FA and its reirLjection onto a BSA stationary phase; the concentration of dl-FA is achieved either by a single evaporation (18) or by an additional extraction on an 
Sample Processing
Ascorbic acid (1 g/L) was added to blank pooled blood donor plasma. Original and published extraction procedures for folic acid analogs were tested, including both organic and solid-phase extraction.
All the organic ex- 
Apparatus
The chromatographic system ( Figure 2 ) consisted of two HPLC columns connected through a Rheodyne 7010 switching valve (equipped with a 600-L sample loop). On-line collection of the dl-FA peak from a reversedphase column (HPLC 1) into the loop of the switching valve is followed by automatic injection of the peak onto the chiral stationary phase (HPLC 2). The choice of the reversed-phase column was dictated by the need to minimize the volume of the dl-FA peak so that it could be injected onto the chiral phase. The use of a narrowbore column (Superspher RP-8, 119 x 2 mm, 4-an particler, Merck no. 16861, flow rate 0.25 mL/min) allowed the dl-FA to be eluted in 500 L, whereas with a conventional column (250 x 4.6 mm, flow rate 1 mL/min), the elution volume was 2 mL (resolution on the chiral phase was satisfactory up to 600 L injected).
[Note: Superspher RP-8 performance is rapidly reduced if pure aqueous phase is used, and therefore the column must be conditioned with methanol :water (30:70 by vol). This allows 100-200 injections to be done.]
Thermostatic control of the chiral column was optimized (35 #{176}C) to improve the chromatographic proffle, i.e., to decrease the retention factor and the peak area:peak height ratio. The BSA bonded silica phase (BSA-BP; Resolvosil-BSA, 150 x 4 mm, 7-jan particles; Macherey Nagel, D#{252}ren, Germany) used by Silan et al. (17) (1000 nmol/L each of dl-FA and 5MTHF) was injected onto HPLC 1 to evaluate the start and the end times of the dl-FA peak. The dead volume between the outlet of the detector and the switching valve was taken into account to program the collection time for the dl-FA peak. Typical width of the dl-FA peak on HPLC 1 is 2 mm (500 pi), and 0.2 mm (50 pL) is added at the start and the end of the collection time so that the total volume collected is 600 p.L.1
Run time for the entire analysis was 18 mm. Chromatographic peaks were quantified by area.
Results and DIscussIon
Injection of the racemic mixture of dl-FA results in very good resolution of the two FA diastereoisomers (Figure 3 enous 1-5MTHF. With our protocol (using ascorbic acid and maintaining the samples at 5 #{176}C), we did not ob- including lumazine, pterin, pterin-6-carboxylic acid, pteroic acid, aminopterin, trimetrexate, and p-aminoacetophenone [the internal standard used in our previous nonstereospecific HPLC assay (23) ]. Except for aminopterin interfering with 5MTHF and p-aminoacetophenone being eluted at 40 mm, all other compounds tested eluted too quickly (retention time <4 mm for HPLC 1), thus leading to interferences with blank plasma. The rapidity of the assay (18 mm) and the simplicity of an isocratic elution are two improvements in the present method compared with other published procedures (16) (17) (18) (19) ). Thus, we tested the precision of the assay without an internal standard, and found a CV of <5% for the intra-assay reproducibility and, as predicted, a higher interassay reproducibility (CV <15%). Electrochernical detection of FA was initially reported by Birmingham and Greene (26) , who used amperometry. We chose coulometric detection to improve both sensitivity and selectivity of the analysis. The oxidation curve (plot of the signal as a function of the potential applied on E2 with El set at 0 V) suggests that FA exhibits at least two oxidizable functional groups, one fully oxidizable at -0.65 V (probably the primary amine), the other being fully oxidizable at much higher potential (>1 V) (Figure 4) . Optimization of the potential applied on El is shown in Figure 5 . Plot of the signal recorded on E2 as a function of the potential applied on (Figure 3) . One is from a child receiving meth- In conclusion, the present stereospecific HPLC assay represents a substantial improvement over existing methods for FA diastereoisomer analysis. This assay is particularly suitable for large-scale analysis and thus is fully applicable to pharmacokinetic investigations currently being undertaken on patients in our center.
